Ref: FOI/GS/ID 6797

22 June 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the incidence and treatment of melanoma and renal cell carcinoma.

You asked:
Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Avelumab + Axitinib
b. Axinitib
c. Cabozantinib
d. Everolimus
e. Lenvantinib + Everolimus
f. Nivolumab
g. Nivolumab + Ipilimumab
h. Pazopanib
i. Pembrolizumab + Axitinib
j. Sunitinib
k. Temsirolimus
l. Tivozanib
m. Other
Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib + Trametinib
d. Encorafenib + Binimetinib
e. Ipilimumab
f. Ipilimumab + Nivolumab
g. Nivolumab
h. Pembrolizumab

i.   Trametinib

j.   Vemurafenib

k.   Vemurafenib + Cobimetinib

l.   Other active systemic anti-cancer therapy

m. Palliative care only

3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

a. Cobimetinib

b. Dabrafenib

c. Dabrafenib + Trametinib

d. Encorafenib + Binimetinib

e. Ipilimumab

f.   Ipilimumab + Nivolumab

g. Nivolumab

h. Pembrolizumab

i.   Trametinib

j.   Vemurafenib

k.   Vemurafenib + Cobimetinib

l.   Other active systemic anti-cancer therapy

m. Palliative care only

Trust response:

Q1.

a. 2

b. 3

c. 9

d. 2

e. 0

f.   7

g. 2

h. 16

i.   0

j.   8

k. 0

l.   0

m. 4

Q2.

a. 0

b. 0

c. 17

d. 7

e. 3

f.   1

g. 11

h. 41

i.   0

j.   1

k. 0

l.   0

m. Unknown

For those left blank on Q3 – this is because we are unable to differentiate between metastatic/non metastatic disease with the data we have available.

3.
a. 0
b. 0
c.
d.
e. 3
f.
g.
h.
i. 0
j. 1
k. 0
l.
m. Unknown